Table 4 .

Model 1—Inferential statistics for mean EBA

			Mean		Mean vs. rifafour
Parameter	Treatment	n	Estimate	95% BCI	Estimate	95% BCI
EBA(0–14)	J (N=15)	15	0.074	[0.010; 0.145]	−0.073	[−0.185; 0.042]
	J-Z (N=15)	15	0.133	[0.065; 0.204]	−0.013	[−0.128; 0.101]
	J-Pa (N = 15)	15	0.101	[0.056; 0.146]	−0.045	[−0.147; 0.055]
	Pa-Z (N = 15)	15	0.154	[0.100; 0.207]	0.007	[−0.098; 0.113]
	Pa-Z-M (N = 15)	15	0.248	[0.087; 0.430]	0.102	[−0.082; 0.304]
	Rifafour (N = 10)	10	0.146	[0.055; 0.238]
EBA(0–2)	J (N = 15)	15	−0.002	[−0.086; 0.084]	−0.156	[−0.316; 0.000]
	J-Z (N = 15)	15	0.069	[−0.038; 0.170]	−0.085	[−0.254; 0.081]
	J-Pa (N = 15)	15	0.105	[0.019; 0.187]	−0.049	[−0.210; 0.105]
	Pa-Z (N = 15)	15	0.179	[0.079; 0.277]	0.025	[−0.142; 0.187]
	Pa-Z-M (N = 15)	15	0.313	[0.164; 0.460]	0.159	[−0.040; 0.355]
	Rifafour (N = 10)	10	0.154	[0.021; 0.290]
EBA(2 -14)	J (N = 15)	15	0.086	[0.019; 0.170]	−0.059	[−0.185; 0.075]
	J-Z (N = 15)	15	0.144	[0.066; 0.229]	−0.001	[−0.132; 0.133]
	J-Pa (N = 15)	15	0.100	[0.053; 0.148]	−0.044	[−0.160; 0.072]
	Pa-Z (N = 15)	15	0.149	[0.093; 0.203]	0.004	[−0.114; 0.124]
	Pa-Z-M (N = 15)	15	0.238	[0.046; 0.455]	0.093	[−0.124; 0.330]
	Rifafour (N = 10)	10	0.145	[0.037; 0.251]

Notes. Treatment group: J = TMC207, J-Z = TMC207 + Pyrazinamide, J-Pa = TMC207 + PA-824, Pa-Z = PA-824 + Pyrazinamide, Pa-Z-M = PA-824 + Pyrazinamide + Moxifloxacin, Rifafour = Rifafour e-275^®. EBA: early bactericidal activity over Day to Day ; BCI: Bayesian credibility interval; n = number of patients in each category.